Abstract 575
Background
People with dementia have poorer cancer outcomes than those without. Little information exists concerning implications of comorbid cancer-dementia for people having cancer treatment in an ambulatory care setting. The purpose of this focused ethnography is to characterise the environment, behaviour and processes that comprise the setting, and to explore what constitutes ‘good care’ in this context.
Trial design
The aim of this focused ethnography is to establish an empirically-based conceptual foundation to inform development of innovations to improve the way treatment and support is offered to people with dementia having cancer treatment. Objectives include: Understanding the physical fabric of the ambulatory care environment, and how this shapes patterns of behaviour and processes; Understanding the actions of those involved in the receipt or provision of care for people with dementia having cancer treatment, through exploration of interactions, perceptions, and language. Understanding the processes involved in care delivery, and how these shape treatment and support offered to patients. Identify characteristics that constitute ‘good care’ and gain an understanding of barriers and facilitators. Identify which aspects of the ambulatory care setting are amenable to modification to meet the needs of this complex population. This project will allow formation of a rich picture of the cultural context in which behaviour, environment and processes are situated, and identify ways in which the organisation of care might be structured to provide a person-centred service for people with dementia. Participants: Participation will be invited from people with dementia having cancer treatment (n ≤ 10), informal carers (n ≤ 10), and staff members (oncologists, nurses, radiographers, support workers, administrative staff, and allied health professionals) (n ≤ 30). Methods: Data will be collected via observations, interviews and document analysis. Data will be analysed using constant comparison, informed by the analytic tradition of grounded theory (Glaser & Strauss 1967), to allow the researchers to establish an empirically-based conceptual and theoretical foundation that is grounded in the original data.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Naomi Farrington.
Funding
National Institute for Health Research, United Kingdom.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5603 - Development of a comprehensive next-generation targeted sequencing assay for detection of gene-fusions in solid tumors
Presenter: Vinay Mittal
Session: Poster Display session 3
Resources:
Abstract
4952 - Next-generation sequencing for better treatment strategy of cancer of unknown primary (CUP)
Presenter: Kang Kook Lee
Session: Poster Display session 3
Resources:
Abstract
4590 - Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease.
Presenter: Michele Ghidini
Session: Poster Display session 3
Resources:
Abstract
3696 - Ultra-sensitive detection of circulating tumor DNA identifies patients in high risk of recurrence in early stages melanoma
Presenter: Filip Janku
Session: Poster Display session 3
Resources:
Abstract
4295 - Identification of the founder BRCA1 mutation c.4117G>T (p.Glu1373*) recurring in Abruzzo and Lazio regions of Central Italy and predisposing to breast/ovarian and BRCA1-related cancers
Presenter: Daniela Di Giacomo
Session: Poster Display session 3
Resources:
Abstract
2214 - Enzalutamide (ENZA) and Apalutamide (APA) In vitro chemical reactivity studies and Activity in a Mouse Drug Allergy Model (MDAM)
Presenter: Mausumee Guha
Session: Poster Display session 3
Resources:
Abstract
5044 - Influence of genetic variation in COMT on cisplatin-induced nephrotoxicity in cancer patients.
Presenter: Bram Agema
Session: Poster Display session 3
Resources:
Abstract
3293 - Cardioprotective and anti-inflammatory effects of Empagliflozin during treatment with Doxorubicin: a cellular and preclinical study
Presenter: Vincenzo Quagliariello
Session: Poster Display session 3
Resources:
Abstract
3324 - Breast Cancer Organoids Model Treatment Response of HER2 Targeted Therapy in HER2-mutant Breast Cancer
Presenter: Xuelu Li
Session: Poster Display session 3
Resources:
Abstract
2115 - Preclinical in vivo screening to predict responder patients depend on EGFR status
Presenter: Yejin Kim
Session: Poster Display session 3
Resources:
Abstract